|
Name |
(4S,4aR,5aS,9E,9aR,9bR)-2-[(E)-hex-4-enoyl]-1,4,4a,8-tetrahydroxy-9-[(2E,4E)-1-hydroxyhexa-2,4-dienylidene]-4,5a,7,9b-tetramethyl-9aH-dibenzofuran-3,6-dione
|
Molecular Formula | C28H34O9 | |
IUPAC Name* |
(4S,4aR,5aS,9E,9aR,9bR)-2-[(E)-hex-4-enoyl]-1,4,4a,8-tetrahydroxy-9-[(2E,4E)-1-hydroxyhexa-2,4-dienylidene]-4,5a,7,9b-tetramethyl-9aH-dibenzofuran-3,6-dione
|
|
SMILES |
C/C=C/CCC(=O)C1=C([C@]2([C@H]3/C(=C(/C=C/C=C/C)\O)/C(=C(C(=O)[C@]3(O[C@]2([C@@](C1=O)(C)O)O)C)C)O)C)O
|
|
InChI |
InChI=1S/C28H34O9/c1-7-9-11-13-16(29)18-20(31)15(3)22(32)26(5)21(18)25(4)23(33)19(17(30)14-12-10-8-2)24(34)27(6,35)28(25,36)37-26/h7-11,13,21,29,31,33,35-36H,12,14H2,1-6H3/b9-7+,10-8+,13-11+,18-16-/t21-,25-,26+,27+,28-/m1/s1
|
|
InChIKey |
WQBJMULJHJGKBM-UWHOGNIDSA-N
|
|
Synonyms |
Dihydrobisvertinolone
|
|
CAS | NA | |
PubChem CID | 11409703 | |
ChEMBL ID | NA |
Chemical Classification: |
|
|
---|
Endophyte ID | Endophyte Name | Family | Genus | Taxonomy ID | GenBank ID | Closest GenBank ID | Reference | |
---|---|---|---|---|---|---|---|---|
Endophyte ID | Endophyte Name | Family | Genus | Taxonomy ID | GenBank ID | Closest GenBank ID | Reference |
Bioactivity Name | Target ID | Target Name | Target Type | Target Organism | Target Organism ID | Potency of Bioactivity | Activity Type | Value | Unit | Endophyte ID | Endophyte Name | |
---|---|---|---|---|---|---|---|---|---|---|---|---|
Bioactivity Name | Target ID | Target Name | Target Type | Target Organism | Target Organism ID | Potency of Bioactivity | Activity Type | Value | Unit | Endophyte ID | Endophyte Name |
Molecular Weight: | 514.6 | ALogp: | 2.6 |
HBD: | 5 | HBA: | 9 |
Rotatable Bonds: | 6 | Lipinski's rule of five: | Rejected |
Polar Surface Area: | 162.0 | Aromatic Rings: | 3 |
Heavy Atoms: | 37 | QED Weighted: | 0.151 |
Caco-2 Permeability: | -5.332 | MDCK Permeability: | 0.00001830 |
Pgp-inhibitor: | 0.314 | Pgp-substrate: | 0.96 |
Human Intestinal Absorption (HIA): | 0.056 | 20% Bioavailability (F20%): | 0.002 |
30% Bioavailability (F30%): | 0.003 |
Blood-Brain-Barrier Penetration (BBB): | 0.097 | Plasma Protein Binding (PPB): | 86.82% |
Volume Distribution (VD): | 0.908 | Fu: | 9.41% |
CYP1A2-inhibitor: | 0.001 | CYP1A2-substrate: | 0.614 |
CYP2C19-inhibitor: | 0.014 | CYP2C19-substrate: | 0.741 |
CYP2C9-inhibitor: | 0.006 | CYP2C9-substrate: | 0.011 |
CYP2D6-inhibitor: | 0.001 | CYP2D6-substrate: | 0.039 |
CYP3A4-inhibitor: | 0.529 | CYP3A4-substrate: | 0.914 |
Clearance (CL): | 5.162 | Half-life (T1/2): | 0.213 |
hERG Blockers: | 0.008 | Human Hepatotoxicity (H-HT): | 0.089 |
Drug-inuced Liver Injury (DILI): | 0.931 | AMES Toxicity: | 0.033 |
Rat Oral Acute Toxicity: | 0.996 | Maximum Recommended Daily Dose: | 0.915 |
Skin Sensitization: | 0.373 | Carcinogencity: | 0.776 |
Eye Corrosion: | 0.047 | Eye Irritation: | 0.066 |
Respiratory Toxicity: | 0.947 |
Similar NPs | Similar Drugs | ||||||
---|---|---|---|---|---|---|---|
NPs ID | NPs 2D Structure | Similarity Score | TTD ID | Drug 2D Structure | Similarity Score | ||
ENC002133 | 0.644 | D0WY9N | 0.259 | ||||
ENC003500 | 0.627 | D08NQZ | 0.231 | ||||
ENC003887 | 0.585 | D0R6RC | 0.228 | ||||
ENC003762 | 0.569 | D0J2NK | 0.228 | ||||
ENC003579 | 0.536 | D02GAC | 0.227 | ||||
ENC003886 | 0.523 | D04VEJ | 0.218 | ||||
ENC004085 | 0.500 | D05AFR | 0.212 | ||||
ENC003250 | 0.444 | D0S0LZ | 0.207 | ||||
ENC004472 | 0.430 | D0G4OD | 0.203 | ||||
ENC005987 | 0.419 | D08LTU | 0.203 |